We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+8.21%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$337M
AUM Growth
+$3.84M
Cap. Flow
-$22.8M
Cap. Flow %
-6.78%
Top 10 Hldgs %
34.36%
Holding
109
New
18
Increased
35
Reduced
37
Closed
13

Top Buys

Rank Stock Value
1
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$9.48M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.12M
3
CAH icon
Cardinal Health
CAH
+$6.74M
4
AGN
Allergan plc
AGN
+$5.18M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$4.64M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$11.3M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.87M
3
GILD icon
Gilead Sciences
GILD
+$5.35M
4
CFNL
Cardinal Financial Corp
CFNL
+$5.03M
5
FRX
FOREST LABORATORIES INC
FRX
+$4.44M

Sector Composition

Rank Sector Weight
1 Healthcare 85%
2 Financials 1.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIND
76
DELISTED
BIND THERAPEUTICS INC
BIND
$1.43M 0.42%
108,535
+48,535
+81% +$475K
AEGR
77
DELISTED
Aegerion Pharmaceuticals
AEGR
$1.35M 0.4%
41,931
-26,464
-39% -$985K
VIRX
78
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.31M 0.39%
958
+256
+36% +$297K
TEVA icon
79
Teva Pharmaceuticals
TEVA
$41.2B
$1.31M 0.39%
25,000
-82,922
-77% -$4.24M
MGNX icon
80
MacroGenics
MGNX
$257M
$1.3M 0.39%
60,000
+40,000
+200% +$841K
SYK icon
81
Stryker
SYK
$130B
$1.26M 0.38%
15,000
-36,100
-71% -$2.95M
AMSG
82
DELISTED
Amsurg Corp
AMSG
$1.24M 0.37%
+27,300
New +$1.25M
IONS icon
83
Ionis Pharmaceuticals
IONS
$9.4B
$1.24M 0.37%
+36,000
New +$1.13M
AET
84
DELISTED
Aetna Inc
AET
$1.22M 0.36%
+15,000
New +$1.14M
IMGN
85
DELISTED
Immunogen Inc
IMGN
$1.17M 0.35%
98,702
+25,000
+34% +$314K
ISRG icon
86
Intuitive Surgical
ISRG
$134B
$1.03M 0.31%
+22,500
New +$993K
EXEL icon
87
Exelixis
EXEL
$13.4B
$1.02M 0.3%
300,000
+5,195
+2% +$17.9K
ANTH
88
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$1.02M 0.3%
37,500
+22,760
+154% +$562K
VOLC
89
DELISTED
VOLCANO CORPORATION COM STK
VOLC
$779K 0.23%
44,221
– –
EIGR
90
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$737K 0.22%
+102
New +$510K
ESRX
91
DELISTED
Express Scripts Holding Company
ESRX
$693K 0.21%
10,000
-27,834
-74% -$1.96M
SRNE
92
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$490K 0.15%
72,535
+23,400
+48% +$176K
MTEM
93
DELISTED
Molecular Templates, Inc.
MTEM
$481K 0.14%
737
-454
-38% -$301K
LXRX icon
94
Lexicon Pharmaceuticals
LXRX
$1.1B
$475K 0.14%
42,115
– –
HAE icon
95
Haemonetics
HAE
$4B
$354K 0.11%
10,047
-10,000
-50% -$334K
ECYT
96
DELISTED
Endocyte, Inc. Common Stock
ECYT
$325K 0.1%
49,297
-19,491
-28% -$220K
ABBV icon
97
AbbVie
ABBV
$435B
– –
-85,494
Closed -$4.39M
BAX icon
98
Baxter International
BAX
$14.2B
– –
-77,633
Closed -$1.98M
BDX icon
99
Becton Dickinson
BDX
$48.2B
– –
-24,600
Closed -$1.59M
CRDF icon
100
Cardiff Oncology
CRDF
$77.2M
– –
-2,730
Closed -$1.13M
1 2 3
4
5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2014 Portfolio in Review

As of Q2 2014, Rhenman & Partners Asset Management held 109 positions worth $337M, up 1.2% from $333M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $22.8M in Q2 2014, closing 13 positions and reducing 37 holdings. Its most notable exit was Pfizer, an estimated $11.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 80% a quarter earlier, followed by Financials.

Against the trend, Rhenman & Partners Asset Management opened a new position in Vertex Pharmaceuticals worth $9.62M.

  • Rhenman & Partners Asset Management's largest Q2 2014 buy was Vertex Pharmaceuticals: 101,600 shares worth $9.62M.
  • Rhenman & Partners Asset Management added most to COVIDIEN PLC COM SHS NEW (IRELAND) in Q2 2014, an estimated $9.48M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2014 reduction was Regeneron Pharmaceuticals, cutting an estimated $9.87M.
  • Rhenman & Partners Asset Management fully exited Pfizer in Q2 2014, selling an estimated $11.3M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 34% of its $337M portfolio in Q2 2014.
  • Rhenman & Partners Asset Management opened 18 new positions and closed 13 in Q2 2014.
  • Rhenman & Partners Asset Management's portfolio value rose 1.2% quarter-over-quarter to $337M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2014, filed 31 Jul 2014.